DTC Stock Overview
Develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Defence Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.25 |
| 52 Week High | CA$2.10 |
| 52 Week Low | CA$0.48 |
| Beta | 1.41 |
| 1 Month Change | 86.57% |
| 3 Month Change | 127.27% |
| 1 Year Change | -32.43% |
| 3 Year Change | -72.16% |
| 5 Year Change | n/a |
| Change since IPO | -51.17% |
Recent News & Updates
Shareholder Returns
| DTC | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 13.6% | 0.3% | -0.1% |
| 1Y | -32.4% | 9.6% | 16.7% |
Return vs Industry: DTC underperformed the Canadian Biotechs industry which returned 15.1% over the past year.
Return vs Market: DTC underperformed the Canadian Market which returned 16.6% over the past year.
Price Volatility
| DTC volatility | |
|---|---|
| DTC Average Weekly Movement | 12.6% |
| Biotechs Industry Average Movement | 12.9% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in CA Market | 18.3% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: DTC has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: DTC's weekly volatility (13%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | Sebastien Plouffe | defencetherapeutics.com |
Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting various cancers; anti-cancer AccuTOX program, which has completed preclinical studies for solid T-cell lymphoma, breast cancer, and melanoma; ARM-X vaccine program, a mesenchymal stem cell-based vaccine targeting cancer; and mRNA vaccination program. It also offers Accuvac for dendritic cell cancer vaccines; a protein-based vaccine formulation against COVID and infectious diseases; and cervical cancer vaccine.
Defence Therapeutics Inc. Fundamentals Summary
| DTC fundamental statistics | |
|---|---|
| Market cap | CA$60.25m |
| Earnings (TTM) | -CA$11.60m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.2x
P/E RatioIs DTC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DTC income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$11.60m |
| Earnings | -CA$11.60m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -44.0% |
How did DTC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 16:05 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Defence Therapeutics Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.